Neglected Pathogens: Bacterial Infections in Persons With Human Immunodeficiency Virus Infection A Review of the Literature (Second of Two Parts)
1993; Wiley; Volume: 13; Issue: 6 Linguagem: Inglês
10.1002/j.1875-9114.1993.tb02758.x
ISSN1875-9114
AutoresDouglas N. Fish, Larry H. Danziger,
Tópico(s)Antimicrobial Resistance in Staphylococcus
ResumoPharmacotherapy: The Journal of Human Pharmacology and Drug TherapyVolume 13, Issue 6 p. 543-563 Neglected Pathogens: Bacterial Infections in Persons With Human Immunodeficiency Virus Infection A Review of the Literature (Second of Two Parts) Douglas N. Fish Pharm.D., Douglas N. Fish Pharm.D. Division of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, ColoradoSearch for more papers by this authorLarry H. Danziger Pharm.D., Corresponding Author Larry H. Danziger Pharm.D. Department of Pharmacy Practice, Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IllinoisDepartment of Pharmacy Practice (M/C 886), College of Pharmacy Room 244, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612.Search for more papers by this author Douglas N. Fish Pharm.D., Douglas N. Fish Pharm.D. Division of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, ColoradoSearch for more papers by this authorLarry H. Danziger Pharm.D., Corresponding Author Larry H. Danziger Pharm.D. Department of Pharmacy Practice, Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IllinoisDepartment of Pharmacy Practice (M/C 886), College of Pharmacy Room 244, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612.Search for more papers by this author First published: November‐December 1993 https://doi.org/10.1002/j.1875-9114.1993.tb02758.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 215 Mirimanoff RO, Glauser MP. Endocarditis during Staphylococcus aureus septicemia in a population of non-drug addicts. Arch Intern Med 1982; 142: 1311–13. 216 Hedstrom SA, Christensson B. Staphylococcus aureus septicaemia and endocarditis at the University Hospital in Lund 1976–1980. Scand J Infect Dis 1983; 41(suppl): 38–46. 217 Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis: comparison of nosocomial and community-acquired infection. J Med 1984; 15: 193–211. 218 Gransden WR, Eykyn SJ, Phillips I. Staphylococcus aureus bacteraemia: 40 episodes in St Thomas's Hospital. Br J Med 1984; 288: 300–3. 219 Bryan CS, Kirkhart B, Brenner ER. Staphylococcal bacteremia: current patterns in nonuniversity hospitals. South Med J 1984; 77: 693–6. 220 Julander I. Unfavorable prognostic factors in Staphylococcus aureus septicemia and endocarditis. Scand J Infect Dis 1985; 17: 179–87. 221 Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80: 83–93. 222 Blume RS, Wolff SM. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. Medicine 1972; 51: 247–80. 223 Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. Recent advances in chronic granulomatous disease. Ann Intern Med 1983; 99: 657–74. 224 Malech HL, Gallin JI. Neutrophils in human diseases. N Engl J Med 1987; 317: 387–94. 225 Raviglione MC, Mariuz P, Pablos-Mendez A, Battan R, Ottuso P, Taranta A. High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control 1990; 18: 64–9. 226 Libman MD, Miller MA, Richards GK. Antistaphylococcal activity of pentamidine. Antimicrob Agents Chemother 1990; 34: 1795–6. 227 Ilowite JS, Baskin MI, Sheetz MS, Abd AG. Delivered dose and regional distribution of aerosolized pentamidine using different delivery systems. Chest 1991; 99: 1139–44. 228 Elwell LP, Ferone R, Freeman GA et al. Antibacterial activity and mechanism of action of 3′-azido-3′-deoxythymidine (BW A509U). Antimicrob Agents Chemother 1987; 31: 274–80. 229 Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974; 129: 725–7. 230 Weinstein HJ. The relationship between the nasal-staphylococcal-carriage state and the frequency of post-operative complications. N Engl J Med 1959; 260: 1303–8. 231 White A. Increased infection rates in heavy nasal carriers of coagulase-positive staphylococci. Antimicrob Agents Chemother 1963; 3: 667–70. 232 Kirmani N, Tuazon CU, Murray HW, Parrish AE, Sheagren JN. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1657–9. 233 Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315: 91–6. 234 Chou M-Y, Brown AE, Blevins A, Armstrong D. Severe pneumococcal infection in patients with neoplastic disease. Cancer 1983; 51: 1546–50. 235 Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR 1981; 30: 410–12, 417–19. 236 Fekety F Jr, Caldwell J, Gump D et al. Bacteria, viruses, and mycoplasmas in acute pneumonia in adults. Am Rev Respir Dis 1971; 104: 499–507. 237 Dorff GJ, Rytel MW, Farmer SG, Scanlon G. Etiologies and characteristic features of pneumonias in a municipal hospital. Am J Med Sci 1973; 266: 349–58. 238 Sullivan R Jr, Dowdle WR, Marine WM, Hierholzer JC. Adult pneumonia in a general hospital: etiology and host risk factors. Arch Intern Med 1972; 129: 935–42. 239 Mufson MA, Kruss DM, Wasil RE, Metzger WI. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med 1974; 134: 505–10. 240 Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, Melzer E. Pneumococcal bacteremia—no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci 1987; 23: 174–80. 241 Barry MA, Craven DE, Finland M. Serotypes of Streptococcus pneumoniae isolated from blood cultures at Boston City Hospital between 1979 and 1982. J Infect Dis 1984; 149: 449–52. 242 Zarkowsky HS, Gallagher D, Gill FM et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109: 579–85. 243 Schwartz PE, Sterioff S, Mucha P, Melton LJ, Offord KP. Postsplenectomy sepsis and mortality in adults. JAMA 1982; 248: 2279–83. 244 O'Neal BJ, McDonald JC. The risk of sepsis in the asplenic adult. Ann Surg 1981; 195: 775–8. 245 Selby C, Hart S, Ispahani P, Toghill PJ. Bacteremia in adults after splenectomy or splenic irradiation. Q J Med 1987; 63: 523–30. 246 Mufson MA, Oley G, Hughey D. Pneumococcal disease in a medium-sized community in the United States. JAMA 1982; 248: 1486–9. 247 Gransden WR, Eykyn S, Phillips I. Pneumococcal bacteraemia: 325 episodes diagnosed at St. Thomas's Hospital. Br Med J 1985; 290: 505–8. 248 Valenti WM, Jenzer M, Bentley DW. Type-specific pneumococcal respiratory disease in the elderly and chronically ill. Am Rev Respir Dis 1978; 117: 233–8. 249 Smart LE, Dougall AJ, Girdwood RWA. New 23-valent pneumococcal vaccine in relation to pneumococcal serotypes in systemic and non-systemic disease. J Infect 1987; 14: 209–15. 250 Straus AL, Hamburger M. Pneumococcal endocarditis in the penicillin era. Arch Intern Med 1966; 118: 190–8. 251 Bayliss R, Clarke C, Oakley CM, Somerville W, Whitfield AGW, Young SEJ. The microbiology and pathogenesis of infective endocarditis. Br Heart J 1983; 50: 513–19. 252 Powderly WG, Stanley SL Jr, Medoff G. Pneumococcal endocarditis: report of a series and review of the literature. Rev Infect Dis 1986; 8: 786–91. 253 Mayosmith MF, Hirsch PJ, Wodzinski SF et al. Acute epiglottitis in adults. N Engl J Med 1986; 314: 1133–9. 254 Devita MA, Wagner IJ. Acute epiglottitis in the adult. Crit Care Med 1986; 14: 1082–3. 255 Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Pneumococcal surveillance working group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987. J Infect Dis 1991; 163: 1273–8. 256 Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae J Infect Dis 1986; 154: 245–56. 257 Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF III. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1–6. 258 Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980; 303: 549–52. 259 Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325–30. 260 Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982; 96: 208–20. 261 Stein DS, Stevens RC, Terry D et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1991; 35: 1705–9. 262 Wormser GP, Horowitz HW, Duncanson FP et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 1991; 151: 688–92. 263 Donowitz GR, Mandell GL. Acute pneumonia. In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 540–55. 264 Stratton CW. Bacterial pneumonias—an overview with emphasis on pathogenesis, diagnosis, and treatment. Heart Lung 1986; 15: 226–44. 265 Moxon ER. Haemophilus influenzae. In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1722–9. 266 Hasan SB, Albu E, Gerst PH. Infectious complications in IV drug abusers. Infect Surg 1988 (March): 218–20, 232. 53 Simon HB, Southwick FS, Moellering RC Jr, Shermen E. Haemophilus influenzae in hospitalized adults: current perspectives. Am J Med 1980; 69: 219–26. 268 Musher DM, Kubitschek KR, Crennan J, Baughn RE. Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae Ann Intern Med 1983; 99: 444–50. 269 Schneerson R, Robbins JB, Parke J Jr et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immunol 1986; 52: 519–28. 270 Anderson P, Betts R. Human adult immunogenicity of protein-coupled pneumococcal capsular antigens of serotypes prevalent in otitis media. Pediatr Infect Dis J 1989; 8(suppl 1): S50–3. 271 Steinhoff MC, Auerbach BS, Nelson KE et al. Antibody responses to Haemophilus influenzae type b vaccines in men with human immunodeficiency virus infection. N Engl J Med 1991; 325: 1837–42. 272 Anderson P. The protective level of serum antibodies to the capsular polysaccharide of H. influenzae type b. J Infect Dis 1984; 149: 1034–5. 273 Heineman HS, Jensen WN, Cooper WM, Braude AI. Hodgkin's disease and Salmonella typhimurium infection. JAMA 1964; 188: 632–4. 274 Wolfe MS, Armstrong D, Louria DB, Blevins A. Salmonellosis in patients with neoplastic disease: a review of 100 episodes at Memorial Cancer Center over a 13–year period. Arch Intern Med 1971; 128: 546–54. 275 Cherubin CE, Neu HC, Imperato PJ, Harvey RP, Bellen N. Septicemia with non-typhoid Salmonella Medicine 1974; 53: 365–76. 276 Mussche MM, Lameire NH, Ringoir SMG. Salmonella typhimurium infections in renal transplant patients: report of five cases. Nephron 1975; 15: 143–50. 277 Samra Y, Snaked Y, Maier MK. Nontyphoid salmonellosis in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1986; 8: 431–40. 278 Izadkhah Z, Mandel AD, Sonnenfeld G. Effect of treatment of mice with sera containing gamma interferon on the course of infection with Salmonella typhimurium strain LT-2. J Interferon Res 1980; 1: 137–45. 279 Kaye D, Gill FA, Hook EW. Factors influencing host resistance to Salmonella infections: the effects of hemolysis and erythrophagocytosis. Am J Med Sci 1967; 254: 205–15. 280 Berkowitz FE. Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis 1991; 13: 1151–62. 281 Bonhoff M, Miller CP. Enhanced susceptibility to Salmonella infection in streptomycin-treated mice. J Infect Dis 1962; 111: 117–27. 282 Pavia AT, Shipman LD, Wells JG et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella J Infect Dis 1990; 161: 255–60. 283 Riley LW, Cohen ML, Seals JE et al. Importance of host factors in human salmonellosis caused by multiresistant strains of Salmonella J Infect Dis 1984; 149: 878–83. 284 Holmberg SD, Osterholm MT, Senger KA, Cohen ML. Drug-resistant Salmonella from animals fed antimicrobials. N Engl J Med 1984; 311: 617–22. 285 MacDonald KL, Cohen ML, Hargrett-Bean NT et al. Changes in antimicrobial resistance of Salmonella isolated from humans in the United States. JAMA 1987; 258: 1496–9. 286 Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. N Engl J Med 1969; 281: 636–40. 287 Neill MA, Opal SM, Heelan J et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114: 195–9. 288 Keusch GT. Salmonellosis. In: JD Wilson, E Braunwald, KJ Isselbacher et al, eds. Harrison's principles of internal medicine, 12th ed. New York: McGraw-Hill, 1990: 609–13. 289 Quinn TC, Stamm WE, Goodell SF et al. The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med 1983; 309: 576–82. 290 Hook EW. Salmonella species (including typhoid fever). In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1700–16. 291 Connolly MJ, Snow MH, Ingham HR. Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome [letter]. J Antimicrob Chemother 1986; 18: 647–8. 292 Levine WC, Buehler JW, Bean NH, Tauxe RV. Epidemiology of nontyphoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. J Infect Dis 1991; 164: 81–7. 293 Centers for Disease Control. Update: Salmonella enteritidis infections and shell eggs—United States, 1990. MMWR 1990; 39: 909–12. 294 Armstrong D, Gold JWM, Dryjanski J et al. Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 738–43. 295 Guerrant RL, Bobak DA. Bacterial and protozoal gastroenteritis. N Engl J Med 1991; 325: 327–40. 296 Bryan JP, Rocha H, Scheld WM. Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones. Rev Infect Dis 1986; 8: 189–207. 297 Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8(suppl 2): S172–81. 298 Cohen ML, Tauxe RV. Drug-resistant Salmonella in the United States: an epidemiologic perspective. Science 1986; 234: 964–9. 299 Cherubin CE, Eng RHK. Quinolones for the treatment of infections due to Salmonella Rev Infect Dis 1991; 13: 343–4. 300 Piddock LJV, Whale K, Wise R. Quinolone resistance in Salmonella: clinical experience [letter]. Lancet 1990; 335: 1459. 301 Preblud SR, Gill CJ, Campos JM. Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp. Antimicrob Agents Chemother 1984; 25: 327–30. 302 Rodriguez C, Olcoz MT, Izquierdo G, Moreno S. Endocarditis due to ampicillin-resistant nontyphoid Salmonella: cure with a third-generation cephalosporin. Rev Infect Dis 1990; 12: 817–19. 303 Rolston KVI, Rodriguez S, Mansell PWA. Antimicrobial therapy for Salmonella infections in the acquired immunodeficiency syndrome (AIDS) [letter]. Ann Intern Med 1988; 108: 309. 304 Cherubin CE, Eng RHK, Smith SM, Goldstein EJC. Cephalosporin therapy for salmonellosis: questions of efficacy and cross-resistance with ampicillin. Arch Intern Med 1986; 146: 2149–52. 305 Asperilla MO, Smego RA Jr, Scott LK. Quinolone antibiotics in the treatment of Salmonella infections. Rev Infect Dis 1990; 12: 873–89. 306 Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378–424. 307 Segreti J, Goodman LJ, Petrak RM, Kaplan RL, Parkhurst GW, Trenholme GM. Serum and fecal concentrations of ciprofloxacin and trimethoprim-sulfamethoxazole in adults with diarrhea. Rev Infect Dis 1988; 10(suppl 1): S206–7. 308 Dan M, Verbin N, Gorea A, Nagar H, Berger SA. Concentrations of ciprofloxacin in human liver, gallbladder, and bile following oral administration. Rev Infect Dis 1988; 10(suppl 1): S125. 309 Klein E, Trautmann M, Hoffman HG. Ciprofloxacin in salmonella infection and abdominal typhoid. Dtsch Med Wochenschr 1986; 111: 1599–1602. 310 Keith BR, White G, Wilson HR. In vivo efficacy of zidovudine (3′-azido-3′-deoxythymidine) in experimental gram-negative bacterial infections. Antimicrob Agents Chemother 1989; 33: 479–83. 311 DuPont HL. Shigella species (bacillary dysentery). In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1716–22. 312 Haltalin KC, Nelson JD, Ring R, Sladoje M, Hinton LV. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70: 970–81. 313 Martin T, Habbick BF, Nyssen J. Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis 1983; 2: 21–6. 314 Connor EB, Connor JD. Extraintestinal manifestations of shigellosis. Am J Gastroenterol 1970; 53: 234–45. 315 Morduchowicz G, Huminer D, Siegman-Igra Y et al. Shigella bacteremia in adults: a report of five cases and review of the literature. Arch Intern Med 1987; 147: 2034–40. 316 Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13(suppl 4): S332–41. 317 Shungu DL, Weinberg E, Gadebusch HH. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother 1983; 23: 86–90. 318 Goodman LJ, Fliegelman RM, Trenholme GM, Kaplan RL. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother 1984; 25: 504–6. 319 Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162: 711–16. 320 Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Habiyaremye I. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986; 29: 883–6. 321 Lolekha S, Patanachareon S, Thanangkul B, Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scand J Infect Dis Suppl 1988; 56: 35–45. 322 Dworkin B, Wormser GP, Abdoo RA, Cabello F, Aguero ME, Sivak SL. Persistence of multiply antibiotic-resistant Campylobacter jejuni in a patient with the acquired immune deficiency syndrome. Am J Med 1986; 80: 965–70. 323 Blaser MJ, Berkowitz ID, LaForce F, Cravens BS, Relier LB, Wang LW. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med 1979; 91: 179–85. 324 Anders B, Lauer BA, Paisley JW, Relier LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982; 1: 131–2. 325 Nolan CM, Johnson KE, Coyle MB, Faler K. Campylobacter jejuni enteritis: efficacy of antibacterial and antimotility drugs. Am J Gastroenterol 1983; 78: 621–6. 326 Michel J, Rogol M, Dickman D. Susceptibility of clinical isolates of Campylobacter jejuni to sixteen antimicrobial agents. Antimicrob Agents Chemother 1983; 23: 796–7. 327 Wang W-LL, Relier LB, Blaser MJ. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli Antimicrob Agents Chemother 1984; 26: 351–3. 328 Linnan MJ, Mascola L, Lou XD et al. Epidemic listeriosis associated with Mexican-style cheese. N Engl J Med 1988; 319: 823–8. 329 Gellin GB, Broome CV, Hightower AW. Geographic differences in listeriosis in the United States [abstr]. Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 47, 1987. 330 Ciesielski CA, Hightower AW, Parsons SK. Listeriosis in the United States 1980–1982. Arch Intern Med 1988; 148: 1416–19. 331 Armstrong D. Listeria monocytogenes. In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1587–93. 332 Schlech WF III. New perspectives on the gastrointestinal mode of transmission in invasive Listeria monocytogenes infection. Clin Invest Med 1984; 7: 321–4. 333 Mackaness GB, Hill WC. The effect of anti-lymphocyte globulin on cell-mediated resistance to infection. J Exp Med 1969; 129: 993–1012. 334 Blanden RV, Langman RE. Cell mediated immunity to bacterial infection in the mouse. Thymus derived cells as effectors of acquired resistance to Listeria monocytogenes.. Scand J Immunol 1972; 1: 379–85. 335 Mackaness GB. Cellular resistance to infection. J Exp Med 1962; 116: 381–406. 336 Kaufmann S, Hahn H, Berger R et al. Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol 1983; 13: 265–68. 337 Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969; 129: 973–92. 338 Njoku-Obi AN, Osebold JW. Studies on mechanisms of immunity in listeriosis. I. Interaction of peritoneal exudate cells from sheep with Listeria monocytogenes in vitro. J Immunol 1962; 89: 187–92. 339 Krahenbuhl JL, Remington JS. In vitro induction of non-specific resistance in macrophages by specifically sensitized lymphocytes. Infect Immunol 1971; 4: 337–41. 340 Osebold JW, Pearson LD, Medin NI. Relationship of antimicrobial cellular immunity to delayed hypersensitivity in listeriosis. Infect Immunol 1974; 9: 354–60. 341 Newborg MR, North RJ. On the mechanism of T cell independent anti-Listeria resistance in nude mice. J Immunol 1980; 124: 571–6. 342 Czuprynski CJ, Campbell PA, Henson PM. Killing of Listeria monocytogenes by human neutrophils and monocytes, but not by monocyte-derived macrophages. J Reticuloendotheliol Soc 1983; 34: 29–44. 343 Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immunol 1988; 56: 2563–9. 344 Lahdevirta J, Maury CPJ, Teppo A-M, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85: 289–91. 345 Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol 1988; 141: 99–104. 346 Jacobs JL, Murray HW. Why is Listeria monocytogenes not a pathogen in the acquired immunodeficiency syndrome? [editorial] Arch Intern Med 1986; 146: 1299–1300. 347 Tuazon CU, Shamsuddin D, Miller H. Antibiotic susceptibility and synergy of clinical isolates of Listeria monocytogenes Antimicrob Agents Chemother 1982; 21: 525–7. 348 Winslow DL, Pankey GA. In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes Antimicrob Agents Chemother 1982; 22: 51–4. 349 Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986; 8: 427–30. 350 Guenther G, Philipson A. Oral trimethoprim as follow-up treatment of meningitis caused by Listeria monocytogenes Rev Infect Dis 1988; 10: 53–5. 351 Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972–1979. Am J Med 1981; 71: 199–209. 352 Macher AM, DeVinatea ML, Daly MJ. AIDS, case for diagnosis. Milit Med 1986; 151: 73–80. 353 Lynn W, Whyte M, Weber J. Nocardia, mycobacteria, and AIDS [letter]. AIDS 1989; 3: 766–7. 354 Berkey P, Bodey GP. Nocardial infection in patients with neoplastic disease. Rev Infect Dis 1989; 11: 407–12. 355 Wilson JP, Turner HR, Kirchner KA, Chapman SW. Nocardial infections in renal transplant patients. Medicine 1989; 68: 38–57. 356 Lerner PI. Nocardia species. In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1926–32. 357 Bross JE, Gordon G. Nocardial meningitis: case reports and review. Rev Infect Dis 1991; 13: 160–5. 358 Peabody JW, Seabury JH. Actinomycosis and nocardiosis. Am J Med 1960; 28: 99–115. 359 Brown RB, Sands M, Ryczak M. Community-acquired pneumonia caused by mixed aerobic bacteria. Chest 1986; 90: 810–14. 360 Dewsnup DH, Wright DN. In vitro susceptibility of Nocardia asteroides to 25 antimicrobial agents. Antimicrob Agents Chemother 1984; 25: 165–7. 361 Gombert ME. Susceptibility of Nocardia asteroides to various antibiotics, including newer beta-lactams, trimethoprim-sulfamethoxazole, amikacin, and N-formimidoylthienamycin. Antimicrob Agents Chemother 1982; 21: 1011–12. 362 Smego R Jr, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983; 143: 711–18. 363 Wallace RJ, Septimus EJ, Williams TW et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia Rev Infect Dis 1982; 4: 315–25. 364 Yu VL. Legionella pneumophila (Legionnaires' disease). In: GL Mandell, RG Douglas, JE Bennett eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 1764–74. 365 Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209–16. 366 Bock B, Edelstein P, Snyder K et al. Legionnaires' disease in renal transplant recipients. Lancet 1978; 1: 410–13. Volume13, Issue6November‐December 1993Pages 543-563 ReferencesRelatedInformation
Referência(s)